

CURRICULUM VITAE

William H. Bradley MD

**Professor
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology**

OFFICE ADDRESS:

Froedtert/MCW Laboratory Building
9200 W Wisconsin Ave
Milwaukee, WI 53226

POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

10/2011 - 06/2013 CTSI Clinical Scholars Program, Medical College of Wisconsin

MILITARY SERVICE:

FACULTY APPOINTMENTS:

07/2008 - 07/2015 Assistant Professor, Division of Gynecologic Oncology, Medical College of Wisconsin,
8701 Watertown Plank Road, Milwaukee, WI 53226

07/2015 - Present Associate Professor, Obstetrics and Gynecology, Gynecologic Oncology, Medical College
of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226

ADMINISTRATIVE APPOINTMENTS:

07/2011 - 06/2013 Faculty Council, Medical College of Wisconsin
12/2013 - Present Academic Incentive Committee

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:

07/2017 - Present Resident Research Committee
05/2019 - Present Ob/Gyn Scholarly Writing Committee

RESEARCH ADMINISTRATIVE APPOINTMENTS:

2010 - 02/2014 GOG Institutional PI
07/2013 - Present Core Member, Phase I and Developmental Therapeutics, NRG
02/2014 - Present NRG Institutional Co-PI

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

Active

Peer Review

| | |
|---------------|--------------------------------------------------------------------------------|
| Title: | Preliminary Validation of a Patient Specific Risk Profile in Ovarian Cancer |
| Source: | Women's Health Research Fund and Falk Medical Research Trust |
| PI: | William H. Bradley, M.D. |
| Direct Funds: | \$50,000 |

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

Regional

William H. Bradley, M.D., Gynecologic Cancer Screening, Women's Health Conference, Milwaukee, WI,
04/27/2012 - Present

Local

William H. Bradley, M.D., Preliminary Validation of a Patient Specific Risk Profile in Ovarian Cancer,
Women's Health Research Program, Medical College of Wisconsin, 08/15/2012 - Present

COMMITTEE SERVICE:

Medical College of Wisconsin

09/2011 - Present Member, Faculty Counsel, Medical College of Wisconsin

05/06/2013 - Present Member, Clinical Cancer Center Scientific Advisory Committee

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian CA, **Bradley WH**, Mathews CA, Liu J, Lowe ES, Bloomfield R, Moore KN. *J Clin Oncol*. 2020 Aug 4;JCO2000799. doi: 10.1200/JCO.20.00799. Online ahead of print. PMID: 32749942
2. ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis. Chen C, Gupta P, Parashar D, Nair GG, George J, Geethadevi A, Wang W, Tsaih SW, **Bradley W**, Ramchandran R, Rader JS, Chaluvally-Raghavan P, Pradeep S. *Oncogene*. 2020 Apr;39(14):2921-2933. doi: 10.1038/s41388-020-1194-7. Epub 2020 Feb 6. PMID: 32029900 Free PMC article.
3. González-Martín A, Pothuri B, Vergote I, Christensen RDP, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, **Bradley WH**, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer *Obstetrical and Gynecological Survey*. 1 January 2020;75(1):29-31.
4. González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G, Baumann K, Jardon K, Redondo A, Moore RG, Vulsteke C, O'cearbhaill RE, Lund B, Backes F, Barretina-Ginesta P, Haggerty AF, Rubio-Pérez MJ, Shahin MS, Mangili G, **Bradley WH**, Bruchim I, Sun K, Malinowska IA, Li Y, Gupta D, Monk BJ, PRIMA/ENGOT-OV26/GOG-3012 Investigators. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med*. 2019 Dec 19;381(25):2391-2402.
5. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, **Bradley W**, Mathews C, Liu J, Lowe ES, Bloomfield R, Disilvestro P. Maintenance Olaparib in Patients With Newly Diagnosed Advanced Ovarian Cancer *Obstetrical and Gynecological Survey*. 1 February 2019;74(2):86-87.
6. Vergote I, Scambia G, O'Malley DM, Van Calster B, Park SY, Del Campo JM, Meier W, Bamias A, Colombo N, Wenham RM, Covens A, Marth C, Raza Mirza M, Kroep JR, Ma H, Pickett CA, Monk BJ, TRINOVA-3/ENGOT-ov2/GOG-3001 investigators. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2019 Jun;20(6):862-876.
7. Harold JA, Uyar D, Rader JS, Bishop E, Nugent M, Simpson P, **Bradley WH**. Adipose-only sentinel lymph nodes: a finding during the adaptation of a sentinel lymph node mapping algorithm with indocyanine green in women with endometrial cancer. *Int J Gynecol Cancer*. 2019 Jan;29(1):53-59.
8. Friedlander M, Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza AM, González-Martín A, Aghajanian C, **Bradley W**, Lowe ES, Bloomfield R, Disilvestro P. Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation

- (BRCAm): Phase III SOLO1 trial *Annals of Oncology*. November 2018;29:ix174-ix175.
9. Harold JA, Free SC, **Bradley WH**. Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer. *Gynecol Oncol Rep*. 2018 Nov;26:91-93. PMID: PMC6223187
 10. Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza AM, González-Martín A, Aghajanian C, **Bradley W**, Lowe ES, Bloomfield R, DiSilvestro P. Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. *Ann Oncol*. 2018 Oct;29 Suppl 8:viii727.
 11. Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, **Bradley W**, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. *N Engl J Med*. 2018 Dec 27;379(26):2495-2505.
 12. von Gruenigen VE, Huang HQ, Cella D, Zevon M, LaChance JA, Walker JL, Salani R, Modesitt SC, Morris RT, **Bradley WH**, Boente MP, Wenzel L. Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. *Gynecol Oncol*. 2018 Jul;150(1):119-126. PMID: PMC6874212
 13. Thaker PH, Brady WE, Lankes HA, Odunsi K, **Bradley WH**, Moore KN, Muller CY, Anwer K, Schilder RJ, Alvarez RD, Fracasso PM. A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology/Gynecologic Oncology Group study. *Gynecol Oncol*. 2017 Nov;147(2):283-290. PMID: PMC5704992
 14. Von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, **Bradley WH**, Rutherford TJ, Higgins RV, Secord AA, Fleming G. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/gynecologic oncology group study *Obstetrical and Gynecological Survey*. 1 August 2017;72(8):481-482.
 15. von Gruenigen VE, Huang HQ, Beumer JH, Lankes HA, Tew W, Herzog T, Hurria A, Mannel RS, Rizack T, Landrum LM, Rose PG, Salani R, **Bradley WH**, Rutherford TJ, Higgins RV, Secord AA, Fleming G. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. *Gynecol Oncol*. 2017 Mar;144(3):459-467. PMID: PMC5570471
 16. Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, **Bradley W**, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G. A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. *Ann Oncol*. 2017 May 01;28(5):996-1004. PMID: PMC5406764
 17. Pommert L, **Bradley W**. *Pediatric Gynecologic Cancers*. *Curr Oncol Rep*. 2017 Jul;19(7):44.
 18. Cohn DE, Sill MW, Walker JL, O'Malley D, Nagel CI, Rutledge TL, **Bradley W**, Richardson DL, Moxley KM, Aghajanian C. Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. *Gynecol Oncol*. 2017 Sep;146(3):477-483. PMID: PMC5570536
 19. Cancer Genome Atlas Research Network, Albert Einstein College of Medicine, Analytical Biological Services, Barretos Cancer Hospital, Baylor College of Medicine, Beckman Research Institute of City of Hope, Buck Institute for Research on Aging, Canada's Michael Smith Genome Sciences Centre, Harvard Medical School, Helen F. Graham Cancer Center & Research Institute at Christiana Care Health Services, HudsonAlpha Institute for Biotechnology, ILSbio, LLC, Indiana University School of Medicine, Institute of Human Virology, Institute for Systems Biology, International Genomics Consortium, Leidos Biomedical, Massachusetts General Hospital, McDonnell Genome Institute at Washington University, Medical College of Wisconsin, Medical University of South Carolina, Memorial Sloan Kettering Cancer Center, Montefiore Medical Center, NantOmics, National Cancer Institute, National Hospital, Abuja, Nigeria, National Human Genome Research Institute, National Institute of Environmental Health Sciences, National Institute on Deafness & Other Communication Disorders, Ontario Tumour Bank, London Health Sciences Centre, Ontario Tumour Bank, Ontario

- Institute for Cancer Research, Ontario Tumour Bank, The Ottawa Hospital, Oregon Health & Science University, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, SRA International, St Joseph's Candler Health System, Eli & Edythe L. Broad Institute of Massachusetts Institute of Technology & Harvard University, Research Institute at Nationwide Children's Hospital, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, University of Bergen, University of Texas MD Anderson Cancer Center, University of Abuja Teaching Hospital, University of Alabama at Birmingham, University of California, Irvine, University of California Santa Cruz, University of Kansas Medical Center, University of Lausanne, University of New Mexico Health Sciences Center, University of North Carolina at Chapel Hill, University of Oklahoma Health Sciences Center, University of Pittsburgh, University of São Paulo, Ribeirão Preto Medical School, University of Southern California, University of Washington, University of Wisconsin School of Medicine & Public Health, Van Andel Research Institute, Washington University in St Louis. Integrated genomic and molecular characterization of cervical cancer. *Nature*. 2017 Mar 16;543(7645):378-384. PMID: PMC5354998
20. Choi J, Ye S, Eng KH, Korthauer K, **Bradley WH**, Rader JS, Kendzioriski C. IPI59: An Actionable Biomarker to Improve Treatment Response in Serous Ovarian Carcinoma Patients. *Stat Biosci*. 2017 Jun;9(1):1-12. PMID: PMC5617361
 21. Hinshaw SJ, Gunderson S, Eastwood D, **Bradley WH**. Endometrial carcinoma: The perioperative and long-term outcomes of robotic surgery in the morbidly obese. *J Surg Oncol*. 2016 Dec;114(7):884-887.
 22. **Bradley WH**, Eng K, Le M, Mackinnon AC, Kendzioriski C, Rader JS. Comparing gene expression data from formalin-fixed, paraffin embedded tissues and qPCR with that from snap-frozen tissue and microarrays for modeling outcomes of patients with ovarian carcinoma. *BMC Clin Pathol*. 2015;15:17. PMID: PMC4582729
 23. Eng KH, Hanlon BM, **Bradley WH**, Szender JB. Prognostic factors modifying the treatment-free interval in recurrent ovarian cancer. *Gynecol Oncol*. 2015 Nov;139(2):228-35. PMID: PMC4630152
 24. Eng KH, Wang S, **Bradley WH**, Rader JS, Kendzioriski C. Pathway index models for construction of patient-specific risk profiles. *Stat Med*. 2013 Apr 30;32(9):1524-35. PMID: PMC3593986
 25. Zakashansky K, **Bradley WH**, Chuang L, Rahaman J, Dottino P. Recent advances in the surgical management of cervical cancer. *Mt Sinai J Med*. 2009 Dec;76(6):567-76.
 26. William H. Bradley, M.D., Peter R. Dottino, M.D., Jamal Rahaman, M.D.. Paraneoplastic Cerebellar Degeneration in Ovarian Carcinoma: Case Report and Review of Immune Function. *International Journal of Gynecologic Oncology*. 2008 Nov-Dec;18(6):1364-7
 27. Konstantin Zakashansky, M.D., William H. Bradley, M.D., Linus Chuang, M.D., Jamal Rahaman, M.D., Peter Dottino, M.D. Recent advances in the surgical management of cervical cancer. *Mt Sinai Journal of Medicine*. 2009 December;76(6): 567-76
 28. Herbert Gretz, M.D., William H. Bradley, M.D., Konstantin Zakashansky, M.D., Deborah Loeb Bohren, Kenneth Kreiger, PhD, Elizabeth Rubin, Alan Skolow, M.D.. Effect of Physician Gender and Specialty on Utilization of Hysterectomy in New York, 2001-2005. *Am J Obstet Gynecol*. 2008 Oct;199(4):347.e1-6
 29. Herbert Gretz, M.D., William H. Bradley, M.D., Konstantin Zakashansky, M.D., Deborah Loeb Bohren, Kenneth Kreiger, Ph.D., Elizabeth Rubin, Alan Skolow, M.D.. Patient Clinic Factors on Utilization of Hysterectomy in New York, 2001-2005. *American Journal of Obstetrics and Gynecology*. 2008 Oct;199(4):349.e1-5
 30. Konstantin Zakashansky, M.D., William H. Bradley, M.D., Farr Nezhat, M.D. New techniques in radical hysterectomy. *Current Opinion in Obstetrics and Gynecology*. 2008 Feb;20(1):14-9.
 31. William H. Bradley, M.D., Paul Lima, MS, Lisa Rogers, BS, Charles Blomquist, PhD, Levi S Downs, M.D. Endometrial carcinoma expresses an increased cathepsin B/D ratio. *Gynecologic Oncology*. 2008 Jan;108(1):84-9.
 32. Jenny Tang M.D., David Bub M.D., William H. Bradley, M.D., Liane Deligdish M.D., Nemish Nagarsheth M.D. Utero-Subfascial Fistula and Emerging Necrotizing Fasciitis resultant from Post-Cesarean Section Endometritis. *Gynecology and Obstetrics, Current Medical Literature*. Vol 12(3):73-76, 2007
 33. Charles A. Leath, III, M.D., Warner K. Huh, M.D., Johnny Hyde, Jr. M.D., David E. Cohn, M.D., Kimberly E. Resnick, M.D., Nicholas P. Taylor, M.D., Matthew A. Powell, M.D., David G. Mutch, M.D., William H. Bradley, M.D., Melissa A. Geller, M.D., Peter A. Argenta, M.D., Michael A. Gold, M.D. A Multi-institutional Review of Outcomes of Endometrial Stromal Sarcoma. *Gynecologic Oncology*. June 2007;105(3):30-634
 34. Geller MA, Argenta P, **Bradley W**, Dusenbery KE, Brooker D, Downs LS Jr, Judson PL, Carson LF, Boente

- MP. Treatment and recurrence patterns in endometrial stromal sarcomas and the relation to c-kit expression. *Gynecol Oncol.* 2004 Dec;95(3):632-6.
35. Chen C, Gupta P, Parashar D, Nair GG, George J, Geethadevi A, Wang W, Tsaih SW, **Bradley W**, Ramchandran R, Rader JS, Chaluvally-Raghavan P, Pradeep S. ERBB3-induced furin promotes the progression and metastasis of ovarian cancer via the IGF1R/STAT3 signaling axis. *Oncogene.* 2020 Apr;39(14):2921-2933. PMID: PMC7346970
36. Zakashansky K, **Bradley WH**, Nezhat FR. New techniques in radical hysterectomy. *Curr Opin Obstet Gynecol.* 2008 Feb;20(1):14-9.
37. **Bradley WH**, Dottino PR, Rahaman J. Paraneoplastic cerebellar degeneration in ovarian carcinoma: case report with review of immune modulation. *Int J Gynecol Cancer.* 2008;18(6):1364-7.
38. Gretz H, **Bradley WH**, Zakashansky K, Nezhat F, Bohren DL, Kreiger K, Rubin E, Sokolow A. Effect of physician gender and specialty on utilization of hysterectomy in New York, 2001-2005. *Am J Obstet Gynecol.* 2008 Oct;199(4):347.e1-6.
39. Gretz H, **Bradley WH**, Zakashansky K, Nezhat F, Rahaman J, Chuang L, Bohren DL, Kreiger K, Rubin E, Sokolow A. Patient clinical factors influencing use of hysterectomy in New York, 2001-2005. *Obstetrical and Gynecological Survey.* January 2009;64(1):22-23.
40. Gretz H, **Bradley WH**, Zakashansky K, Nezhat F, Rahaman J, Chuang L, Bohren DL, Kreiger K, Rubin E, Sokolow A. Patient clinical factors influencing use of hysterectomy in New York, 2001-2005. *Am J Obstet Gynecol.* 2008 Oct;199(4):349.e1-5.
41. **Bradley WH**, Lima PH, Rodgers L, Blomquist CH, Downs LS. Endometrial carcinoma expresses an increased cathepsin B/D ratio. *Gynecol Oncol.* 2008 Jan;108(1):84-9.
42. Leath CA 3rd, Huh WK, Hyde J Jr, Cohn DE, Resnick KE, Taylor NP, Powell MA, Mutch DG, **Bradley WH**, Geller MA, Argenta PA, Gold MA. A multi-institutional review of outcomes of endometrial stromal sarcoma. *Gynecol Oncol.* 2007 Jun;105(3):630-4.
43. **Bradley WH**, Boente MP, Brooker D, Argenta PA, Downs LS, Judson PL, Carson LF. Hysteroscopy and cytology in endometrial cancer. *Obstet Gynecol.* 2004 Nov;104(5 Pt 1):1030-3.
44. Melissa A. Geller, M.D., Peter A. Argenta, M.D., William H. Bradley, M.D., Katherine Dusenbery, M.D., Doris Brooker, M.D., Levi S. Downs, M.D., Patricia L. Judson, M.D., Linda F. Carson, M.D., Matthew P. Boente, M.D. Treatment and Recurrence Patterns in Endometrial Stromal Sarcomas and the Relation to C-Kit Expression. *Gynecologic Oncology.* 95(3):632-636, Dec. 2004
45. William H. Bradley, M.D., Matthew P. Boente, M.D., Peter A. Argenta, M.D., Levi S. Downs, M.D., Patricia L. Judson, M.D., Linda F. Carson, M.D. Hysteroscopy and Cytology in Endometrial Cancer. *Obstetrics and Gynecology.* 104(5 Pt 1):1030-1033, Nov. 2004
46. DiSilvestro P, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian CA, **Bradley WH**, Mathews CA, Liu J, Lowe ES, Bloomfield R, Moore KN. Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. *J Clin Oncol.* 2020 Oct 20;38(30):3528-3537. PMID: PMC8190876
47. Friedlander M, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Lisyanskaya A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, **Bradley WH**, Liu J, Mathews C, Selle F, Lortholary A, Lowe ES, Hettle R, Flood E, Parkhomenko E, DiSilvestro P. Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial. *Lancet Oncol.* 2021 May;22(5):632-642.
48. Coleman RL, Lorusso D, Gennigens C, González-Martín A, Randall L, Cibula D, Lund B, Woelber L, Pignata S, Forget F, Redondo A, Vindeløv SD, Chen M, Harris JR, Smith M, Nicacio LV, Teng MSL, Laenen A, Rangwala R, Manso L, Mirza M, Monk BJ, Vergote I, innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol.* 2021 May;22(5):609-619.
49. Colombo N, Moore K, Scambia G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, **Bradley WH**, Kim JW, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial *Gynecologic Oncology.* 2021.
50. Cara Amanda Mathews, Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana

- Oaknin, Michael Friedlander, Alla Sergeevna Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S. Sonke, Charlie Gourley, Susana N. Banerjee, Amit M. Oza, Antonio González-Martín, Carol Aghajanian, William Hampton Bradley, Elizabeth S. Lowe, Ralph Bloomfield, Paul Disilvestro. Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial. *Journal of Clinical Oncology*. DOI: 10.1200/JCO.2019.37.15_suppl.5541 *Journal of Clinical Oncology* 37, no. 15_suppl (May 20, 2019) 5541-5541..
51. Yin X, Davi R, Lamont EB, Thaker PH, **Bradley WH**, Leath CA 3rd, Moore KM, Anwer K, Musso L, Borys N. Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized Trial. *JCO Clin Cancer Inform*. 2023 Jan;7:e2200103.
 52. Summey RM, Rader JS, Moh M, **Bradley W**, Uyar D, Bishop E, McAlarnen L, Hopp E. A case series of triplet anti-hormonal therapy in androgen receptor-positive recurrent adult ovarian granulosa cell tumor *Gynecologic Oncology Reports*. December 2022;44.
 53. McAlarnen LA, Maurer JE, Knaub A, Hopp E, Streitenberger K, Bishop E, **Bradley W**, Rader J, Uyar D. Same-Day Discharge After Robotic Hysterectomy: A Resource Utilization and Quality Improvement Project. *WMJ*. 2022 Oct;121(3):243-246.
 54. DiSilvestro P, Banerjee S, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, **Bradley W**, Mathews C, Liu J, McNamara J, Lowe ES, Ah-See ML, Moore KN, SOLO1 Investigators. Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial. *J Clin Oncol*. 2023 Jan 20;41(3):609-617. PMID: PMC9870219
 55. Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, **Bradley WH**, Bone KM, Rader JS, Pradeep S, Chaluvally-Raghavan P. Correction to: Parashar et al. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance (*Cancers*, (2022), 14, 958) *Cancers*. May-2 2022;14(10).
 56. Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, **Bradley WH**, Rader JS, Pradeep S, Chaluvally-Raghavan P. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance *Cancers*. February-2 2022;14(4).
 57. O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, **Bradley WH**, Hietanen S, O'Malley DM, Dørum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, González-Martín A. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study *Gynecologic Oncology*. 2022.
 58. Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, **Bradley WH**, Holmes E, Lowe ES, DiSilvestro P. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial *The Lancet Oncology*. December 2021;22(12):1721-1731.
 59. Geethadevi A, Nair A, Parashar D, Ku Z, Xiong W, Deng H, Li Y, George J, McAllister DM, Sun Y, Kadamberi IP, Gupta P, Dwinell MB, **Bradley WH**, Rader JS, Rui H, Schwabe RF, Zhang N, Pradeep S, An Z, Chaluvally-Raghavan P. Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth. *Cancer Res*. 2021 Oct 15;81(20):5336-5352. PMID: PMC8530981
 60. Colombo N, Moore K, Scambia G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, **Bradley WH**, Kim JW, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial. *Gynecol Oncol*. 2021 Oct;163(1):41-49. PMID: PMC9555119
 61. Thaker PH, **Bradley WH**, Leath CA 3rd, Gunderson Jackson C, Borys N, Anwer K, Musso L, Matsuzaki J, Bshara W, Odunsi K, Alvarez RD. GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced Epithelial Ovarian Cancer: A Phase I Dose-escalation Study. *Clin Cancer Res*. 2021 Oct 15;27(20):5536-5545. PMID: PMC9338778
 62. Pommert L, **Bradley W**. *Pediatric Gynecologic Cancers*. *Curr Oncol Rep*. 2017 Jul;19(7):44.
 63. McAlarnen LA, Small C, Tostrud L, Pan AY, Erickson B, Bedi M, **Bradley WH**. Considerations for

- pharmacologic thromboprophylaxis following inpatient brachytherapy for gynecologic malignancies. *Brachytherapy*. 2023;22(5):630-639. PMID: PMC10757857
64. Mackinnon AC Jr, Johnson CM, Robin A, Christiansen L, Hanbazazh M, Summey RM, Chandrashaker D, Harada S, **Bradley WH**. Pathologic, immunologic, and clinical analysis of the microsatellite instability phenotype in endometrial carcinoma. *Hum Pathol*. 2023 Sep;139:80-90.
 65. Arend R, Dholakia J, Castro C, Matulonis U, Hamilton E, Jackson CG, LyBarger K, Goodman HM, Duska LR, Mahdi H, ElNaggar AC, Kagey MH, Liu A, Piper D, Barroilhet LM, **Bradley W**, Sachdev J, Sirard CA, O'Malley DM, Birrer M. DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma. *Gynecol Oncol*. 2023 May;172:82-91.
 66. Summey RM, Rader JS, Moh M, **Bradley W**, Uyar D, Bishop E, McAlarnen L, Hopp E. A case series of triplet anti-hormonal therapy in androgen receptor-positive recurrent adult ovarian granulosa cell tumor. *Gynecol Oncol Rep*. 2022 Dec;44:101118. PMID: PMC9791298
 67. Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, **Bradley WH**, Bone KM, Rader JS, Pradeep S, Chaluvally-Raghavan P. Correction: Parashar et al. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. *Cancers* 2022, *14*, 958. *Cancers* (Basel). 2022 May 16;14(10). PMID: PMC9140135
 68. O'Cearbhaill RE, Pérez-Fidalgo JA, Monk BJ, Tusquets I, McCormick C, Fuentes J, Moore RG, Vulsteke C, Shahin MS, Forget F, **Bradley WH**, Hietanen S, O'Malley DM, Dørum A, Slomovitz BM, Baumann K, Selle F, Calvert PM, Artioli G, Levy T, Kumar A, Malinowska IA, Li Y, Gupta D, González-Martín A. Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study. *Gynecol Oncol*. 2022 Jul;166(1):36-43. PMID: PMC10025898
 69. Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, **Bradley WH**, Bone KM, Rader JS, Pradeep S, Chaluvally-Raghavan P. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. *Cancers* (Basel). 2022 Feb 15;14(4). PMID: PMC8870411
 70. Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Oza A, González-Martín A, Aghajanian C, **Bradley WH**, Holmes E, Lowe ES, DiSilvestro P. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol*. 2021 Dec;22(12):1721-1731.
 71. Wenzel L, Huang HQ, Cella D, McKinney CO, Zevon MA, LaChance JA, Walker JL, Salani R, Modesitt SC, Morris RT, **Bradley WH**, Boente MP, von Gruenigen VE. Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study. *Gynecol Oncol*. 2021 Nov;163(2):392-397. PMID: PMC8805698
 72. Mutch D, Voulgari A, Chen XM, **Bradley WH**, Oaknin A, Perez Fidalgo JA, Montosa FG, Herraes AC, Holloway RW, Powell MA, Nowicka M, Schaefer G, Merchant M, Yan Y. Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer. *Cancer*. 2024 Jun 01;130(11):1940-1951.
 73. Uyar D, Michener CM, Bishop E, Hopp E, Simpson P, Zhang L, Rader JS, Rose PG, Mahdi HS, Debernardo R, Christian Q, **Bradley W**. Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer *Frontiers in Oncology*. 2024;14.

Books, Chapters, and Reviews

1. William H. Bradley M.D., Farr Nezhat M.D. Hysteroscopy and Endometrial Cancer. *Nezhat's Operative Gynecological Laparoscopy with Hysteroscopy: Principles and Technique*. Cambridge University Press, New York, NY. 2008. Pp 577-582
2. William H. Bradley M.D., Jamal Rahaman M.D. *Pediatric Gynecologic Cancer*. Pediatric, Adolescent and Young Adult Gynecology Blackwell Publishing, Oxford, UK. Pp 390-397
3. Konstansin Zakashansky M.D., William H. Bradley M.D., Farr Nezhat M.D. Update in Radical Hysterectomy. *Current Opinions in Obstetrics and Gynecology*. 2008 Feb;20(1):14-9. Review.
4. **Bradley WH**, Nezhat F. Robot-assisted laparoscopy *Nezhat's Operative Gynecologic Laparoscopy and Hysteroscopy*. 1 January 2008:577-581.

5. **Bradley W, Rahaman J.** Pediatric Gynecologic Cancer Pediatric, Adolescent, & Young Adult Gynecology. 6 May 2009:390-396.

Abstracts

1. William H. Bradley, M.D., Analisa DiFeo, Ph.D., Jamal Rahaman, M.D., Peter Dottino, M.D., John Martignetti, M.D., Ph.D. The tumor suppressor KLF6, lost in a majority of ovarian cancer cases, represses VEGF expression levels. Abstract#130, Volume 120, Issue 1, Supplement 1. (March 2011)
2. Valentin Kolev, M.D., Rachel Zhang, William H. Bradley, M.D., Rashida N'gouamba, Peter Dottino, M.D., Jamal Rahaman, M.D., Monica Hayes, M.D. Sequential chemotherapy and radiation therapy for the adjuvant treatment of uterine papillary serous carcinoma. Abstract#217, Volume 120, Issue 1, Supplement 1. (March 2011)
3. B. Bonacci, B. Wakim, L. Reddy, E. Hammelev, Janet Osborne, M.D., William H. Bradley, M.D., J. Verbsky, Denise Uyar, M.D. Induced T regulatory cells: A potential role in the tumorigenesis of endometrial cancer. Abstract #199, Volume 116, Issue 3, Supplement 1. (March 2010)
4. William H. Bradley, M.D., Konstantin Zakashansky, M.D., Nimesh P. Nagarsheth, M.D., Farr Nezhat, M.D., George Hagopian, M.D., Herb Gretz, M.D., Linus Chuang, M.D., Peter Dottino, M.D., Jamal Rahaman, M.D.. Laparoscopic Management of Endometrioid Carcinoma. Gynecologic Oncology. Abstract #163. Volume 108, Issue 3, Supplement 1, Pages S1-S182 (March 2008)
5. Konstantin Zakashansky, M.D., William H. Bradley, M.D., Peter Dottino, M.D., Valentin Kolev, M.D., Nimesh P. Nagarsheth, M.D., Farr R. Nezhat, M.D., Herbert Gretz, M.D., Jamal Rahaman, M.D. In Vitro Platinum Resistance in the Extreme Drug Resistance (EDR) Assay as a Predictor of Progression Free Interval in Primary Advanced Stage Ovarian Cancer. Gynecologic Oncology. Abstract #104. Volume 108, Issue 3, Supplement 1, Pages S1-S182 (March 2008)
6. Konstantin Zakashansky, M.D., William H. Bradley, M.D., Jamal Rahaman, M.D., Peter Dottino, M.D., Cathey Ester, PhD, William A. Ricketts, PhD. Comparative Genomic Hybridization (CGH) Predicts Time to Recurrence in Primary Ovarian Carcinoma. Gynecologic Oncology. Abstract #89. Volume 108, Issue 3, Supplement 1, Pages S1-S182 (March 2008)
7. William H. Bradley, M.D., Paul Lima, MS, Lisa Rogers, BS, Charles Blomquist, PhD, Levi S Downs, M.D. Enzymatic Activity of Cathepsin B is Increased in Malignant Endometrial Tissue. Poster Presentation, 52nd Annual Meeting of the Society for Gynecologic Investigation. Abstract #903.
8. William H. Bradley, M.D., Peter Argenta, M.D., Levi Downs, M.D., Patricia Judson, M.D., Linda Carson, M.D., Matthew Boente, M.D.. Implications of Hysteroscopy on Peritoneal Cytology in Endometrial Cancer. Poster, Society of Gynecologic Oncology 35th Annual Meeting, San Diego, California, February 7-11, 2004
9. Melissa Geller, M.D., William H. Bradley, M.D., Patricia Judson, M.D., Levi Downs, M.D., Matthew Boente, M.D., Linda Carson, M.D., Peter Argenta, M.D. Expression of C-kit Antigen in Low and High Grade Endometrial Stromal Sarcomas; Outcomes and Recurrence Patterns as Related to C-Kit. Poster, Society of Gynecologic Oncology 35th Annual Meeting, San Diego, California, February 7-11, 2004
10. Johnny Hyde Jr., Michael A. Gold, Nick P. Taylor, Matthew A. Powell, David G. Mutch, William H. Bradley, Melissa A. Geller, Peter A. Argenta, David E. Cohn, Kimberly E. Resnick, Charles A. Leath III, Warner K. Huh. Endometrial Stromal Sarcoma: A Multi-center Retrospective Review. Society of Gynecologic Oncology 36th Annual Meeting. Miami, FL, March, 2005
11. Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with neoadjuvant chemotherapy in patients with newly diagnosed advanced-stage ovarian cancer. Premal H. Thaker, William Hampton Bradley, Charles A. Leath, Camille Catherine Gunderson, Nicholas Borys, Lauren Musso, Khursheed Anwer, Ronald David Alvarez; Washington University School of Medicine, St. Louis, MO; Medical College of Wisconsin, Milwaukee, WI; University of Alabama Birmingham, Birmingham, AL; University of Oklahoma Health Sciences Center, Oklahoma City, OK; Celsion Corporation, Lawrenceville, NJ; Celsion Corporation, Huntsville, AL; Vanderbilt University, Nashville, TN. 2019 ASCO-SITC Clinical Immuno-Oncology Symposium
12. Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS) M.L.Friedlander, K.N.Moore, N.Colombo, G.Scambia, B.G.Kim, A.Oaknin, A.Lisyanskaya, A.Floquet, A.Leary, G.S.Sonke, C.Gourley, S.Banerjee, A.Oza, A.González-Martín, C.Aghajanian, W.Bradley, E.Lowe, R.Hettle, E.Flood, P.Disilvestro. European Society of Medical Oncology, Asia. Nov 2019
13. Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian

- cancer (OC) and a BRCA mutation (BRCAm) in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS). M.L.Friedlander, K.N.Moore, N.Colombo, G.Scambia, B.G.Kim, A.Oaknin, A.Lisyanskaya, A.Floquet, A.Leary, G.S.Sonke, C.Gourley, S.Banerjee, A.Oza, A.González-Martín, C.Aghajanian, W.Bradley, E.Lowe, R.Hettle, E.Flood, P.Disilvestro. European Society of Medical Oncology, Barcelona, 2019
14. 995PD - Time to second progression (PFS2) and second subsequent therapy (TSST) for patients (pts) with newly diagnosed, advanced ovarian cancer (OC) and a BRCA mutation (BRCAm) treated with maintenance (mt) olaparib (ola): Phase III SOLO1 trial. A.Oaknin, K.Moore, N.Colombo, G.Scambia, B.G.Kim, M.Friedlander, A.Lisyanskaya, A.Floquet, A.Leary, G.S.Sonke, C.Gourley, S.Banerjee, A.M.Oza, A.GonzálezMartín, C.Aghajanian, W.Bradley, E.S.Lowe, R.Bloomfield, P.DiSilvestro. European Society of Medical Oncology, Barcelona, 2019
15. Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. M.Friedlander, K.Moore, N.Colombo, G.Scambia, B.G.Kim, A.Oaknin, A.Lisyanskaya, A.Floquet&A.Leary, G.S.Sonke, C.Gourley, S.Banerjee, A.M.Oza, A.González-Martín, C.Aghajanian, W.Bradley, E.S.Lowe, R.Bloomfield, P.Disilvestro. European Society of Medical Oncology, Asia 2018
16. Maintenance olaparib following platinum-based chemotherapy in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial. K.N. Moore, N. Colombo, G. Scambia, B-G. Kim, A. Oaknin, M. Friedlander, A. Lisyanskaya⁷, A. Floquet⁸, A. Leary, G.S. Sonke, C. Gourley, S. Banerjee, A.M. Oza, A. Gonz alez-Mart ?n, C. Aghajanian, W. Bradley, E.S. Lowe, R. Bloomfield, P. DiSilvestro. European Society of Medical Oncology Congress, Germany 2018